CL2011000730A1 - Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer. - Google Patents

Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer.

Info

Publication number
CL2011000730A1
CL2011000730A1 CL2011000730A CL2011000730A CL2011000730A1 CL 2011000730 A1 CL2011000730 A1 CL 2011000730A1 CL 2011000730 A CL2011000730 A CL 2011000730A CL 2011000730 A CL2011000730 A CL 2011000730A CL 2011000730 A1 CL2011000730 A1 CL 2011000730A1
Authority
CL
Chile
Prior art keywords
antibodies
hybridoma
medicine
vector
prepare
Prior art date
Application number
CL2011000730A
Other languages
English (en)
Spanish (es)
Inventor
Christine Grenier-Caussanel Veronique Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CL2011000730A1 publication Critical patent/CL2011000730A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
CL2011000730A 2008-10-01 2011-04-01 Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer. CL2011000730A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13677208P 2008-10-01 2008-10-01
EP08305631A EP2172485A1 (en) 2008-10-01 2008-10-01 Novel anti CXCR4 antibodies and their use for the treatment of cancer
US17374309P 2009-04-29 2009-04-29

Publications (1)

Publication Number Publication Date
CL2011000730A1 true CL2011000730A1 (es) 2012-02-03

Family

ID=40361774

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000730A CL2011000730A1 (es) 2008-10-01 2011-04-01 Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer.

Country Status (28)

Country Link
US (4) US8557964B2 (cg-RX-API-DMAC7.html)
EP (2) EP2172485A1 (cg-RX-API-DMAC7.html)
JP (1) JP5723279B2 (cg-RX-API-DMAC7.html)
KR (1) KR101671039B1 (cg-RX-API-DMAC7.html)
CN (1) CN102209730B (cg-RX-API-DMAC7.html)
AR (1) AR073748A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009299787B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0920531A2 (cg-RX-API-DMAC7.html)
CA (1) CA2738782C (cg-RX-API-DMAC7.html)
CL (1) CL2011000730A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115572T1 (cg-RX-API-DMAC7.html)
DK (1) DK2342233T3 (cg-RX-API-DMAC7.html)
ES (1) ES2503732T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20146084B (cg-RX-API-DMAC7.html)
HR (1) HRP20140899T1 (cg-RX-API-DMAC7.html)
IL (1) IL212066A (cg-RX-API-DMAC7.html)
MA (1) MA32928B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011003509A (cg-RX-API-DMAC7.html)
NZ (1) NZ592363A (cg-RX-API-DMAC7.html)
PL (1) PL2342233T3 (cg-RX-API-DMAC7.html)
PT (1) PT2342233E (cg-RX-API-DMAC7.html)
RS (1) RS53578B1 (cg-RX-API-DMAC7.html)
RU (1) RU2573897C2 (cg-RX-API-DMAC7.html)
SI (1) SI2342233T1 (cg-RX-API-DMAC7.html)
TW (1) TWI469792B (cg-RX-API-DMAC7.html)
UA (1) UA102867C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010037831A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102969B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
JP2014504147A (ja) * 2010-10-27 2014-02-20 ピエール、ファーブル、メディカマン Ｈｉｖの治療用抗体
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
NL2010658C2 (en) * 2013-04-18 2014-10-21 Bosch Gmbh Robert Thermostat for a hvac.
JP6506280B2 (ja) * 2013-08-02 2019-05-08 ファイザー・インク 抗ｃｘｃｒ４抗体および抗体−薬剤コンジュゲート
JP2016530895A (ja) 2013-09-23 2016-10-06 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 動物細胞を遺伝子改変する改良された方法
AR104413A1 (es) * 2015-04-27 2017-07-19 Pf Medicament Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
CA3004498A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
EP3408378B1 (en) 2016-01-25 2022-01-12 NantCell, Inc. Nk cells with altered cxcl12/cxcr4 signaling
JPWO2017203799A1 (ja) * 2016-05-25 2019-02-28 株式会社東芝 エネルギー管理装置、管理システム、消費電力監視方法及びプログラム
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3052070A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
US20230181635A1 (en) 2018-03-13 2023-06-15 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
WO2025049591A1 (en) * 2023-08-28 2025-03-06 Regeneron Pharmaceuticals, Inc. Anti-cxcr4 antibodies and uses thereof
CN117003876B (zh) * 2023-08-31 2024-06-18 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2006086883A1 (en) * 2005-02-16 2006-08-24 Universite De Montreal Biosensors for monitoring receptor-mediated g-protein activation
EP1871807B1 (en) * 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
CA2724409A1 (en) * 2008-05-14 2009-11-19 Eli Lilly And Company Anti-cxcr4 antibodies

Also Published As

Publication number Publication date
AU2009299787A2 (en) 2011-06-02
ZA201102969B (en) 2011-12-28
JP2012504401A (ja) 2012-02-23
EP2342233B1 (en) 2014-06-25
UA102867C2 (uk) 2013-08-27
WO2010037831A1 (en) 2010-04-08
US20110287451A1 (en) 2011-11-24
CA2738782A1 (en) 2010-04-08
CN102209730B (zh) 2014-11-05
CA2738782C (en) 2017-11-28
AR073748A1 (es) 2010-12-01
EP2172485A1 (en) 2010-04-07
RS53578B1 (sr) 2015-02-27
DK2342233T3 (da) 2014-09-29
BRPI0920531A2 (pt) 2021-02-23
PL2342233T3 (pl) 2014-11-28
MX2011003509A (es) 2011-05-02
SI2342233T1 (sl) 2014-10-30
PT2342233E (pt) 2014-10-03
HRP20140899T1 (hr) 2014-11-07
US20140050661A1 (en) 2014-02-20
RU2573897C2 (ru) 2016-01-27
CN102209730A (zh) 2011-10-05
US20110020218A1 (en) 2011-01-27
TW201018483A (en) 2010-05-16
TWI469792B (zh) 2015-01-21
AU2009299787A1 (en) 2010-04-08
EP2342233A1 (en) 2011-07-13
AU2009299787B2 (en) 2015-06-18
IL212066A (en) 2015-05-31
KR20110081229A (ko) 2011-07-13
NZ592363A (en) 2012-08-31
RU2011115559A (ru) 2012-11-10
IL212066A0 (en) 2011-06-30
JP5723279B2 (ja) 2015-05-27
US8557964B2 (en) 2013-10-15
CY1115572T1 (el) 2017-01-04
HK1163119A1 (en) 2012-09-07
US9388248B2 (en) 2016-07-12
KR101671039B1 (ko) 2016-11-01
MA32928B1 (fr) 2012-01-02
GEP20146084B (en) 2014-05-13
ES2503732T3 (es) 2014-10-07
US20110294156A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
CL2011000730A1 (es) Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer.
CL2014001254A1 (es) Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
CL2013002203A1 (es) Molecula de union a antigeno (abm) que se une al antigeno carcinoembrionario humano (cea) unido a membrana; anticuerpo que se une a cea unido a membrana; polinucleotido que los codifica; vector; celula huesped; composicion que comprende al abm o al anticuerpo; y su uso para tratar un cancer que expresa niveles anormales de cea.
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
AR079551A1 (es) Anticuerpos anti-her3 y usos de los mismos
CL2011002784A1 (es) Anticuerpo anti-egfl7; acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion que lo comprende, y su uso para tratar un tumor, cancer o un trastorno proliferativo.
CL2009000379A1 (es) Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
MX372679B (es) Moleculas de union para bcma y cd3.
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
GB201020995D0 (en) Biological materials and uses thereof
CL2014000181A1 (es) Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11).
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CL2014000631A1 (es) Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
AR088941A1 (es) Anticuerpos anti-fgfr2 y sus usos
MX2010000537A (es) Anticuerpos monoclonales contra glipicano-3.
CL2015002526A1 (es) Anticuerpos anti-ox40 y métodos de uso de los mismos.(divisional de 545-13).
PH12015501651A1 (en) Antibody constructs for cdh19 and cd3
BR112015010740A2 (pt) Agentes para tratamento de doenças cancerosas expressando claudina
EA201492101A1 (ru) Антитела против fcrn
CL2011003182A1 (es) Anticuerpo anti-vegf o fragmento de union del mismo que comprende cdrs con secuencias aminoacidicas con hasta 17 mutaciones respecto a las secuencias cdrs del anticuerpo bavacizumab o ranibizumab; acido nucleico; vector; celula huesped; metodo de produccion; conjugado anticuerpo-farmaco; composicion; y uso para tratar cancer.
CL2015000092A1 (es) Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer.
CL2011002039A1 (es) Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.
CL2011002304A1 (es) Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer.
CL2014000076A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de la enzima dipeptidilpeptidasa iv (dpp-iv); proceso para prepararlos; sal de los compuestos; compuestos intermediarios; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y su uso para tratar diabetes mellitus tipo ii u obesidad.
CL2013000074A1 (es) Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.